Effects of Accelerated rTMS on Sleep Architecture in Chronic Insomnia Disorder

Clinical and Neurophysiological Effects of Accelerated rTMS on Sleep Architecture in Chronic Insomnia Disorder: A Prospective Pilot Study

Chronic insomnia disorder is a common condition in which people have ongoing difficulty falling asleep, staying asleep, or waking too early. It affects about 10-12% of adults and can lead to daytime problems, stress, and other health issues. Current treatments include talk therapy (cognitive behavioral therapy for insomnia) and sleep medications, but medications can have side effects and may not work well over the long term.

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment that uses magnetic pulses applied to the scalp to stimulate specific areas of the brain. It has shown promise in improving sleep quality in people with insomnia by targeting a brain region called the left dorsolateral prefrontal cortex, which plays a role in the overactive brain arousal thought to cause insomnia.

The purpose of this study is to find out whether an accelerated course of rTMS using the EXOMIND™ device can improve sleep in adults with chronic insomnia disorder. The study will enroll approximately 70 participants aged 18 to 85 years at a single site in San Francisco. Participants will receive 6 rTMS sessions (3 times per week for 2 weeks). Each session lasts about 25 minutes.

The study has three phases: a screening phase (up to 25 days) to confirm eligibility using sleep questionnaires and at-home sleep monitoring, a 2-week open-label treatment phase, and a follow-up phase with visits at 1 month and 3 months after the last treatment session. Total participation lasts up to approximately 139 days.

The main goal is to measure whether insomnia severity improves after treatment, using a standard questionnaire called the Insomnia Severity Index (ISI). The study will also measure changes in objective sleep patterns (such as how long it takes to fall asleep, time spent in deep sleep, and total sleep time) recorded by a home sleep monitoring device, as well as changes in sleep quality, stress levels, and overall clinical impression of improvement.

This is an open-label pilot study, meaning all participants will receive the rTMS treatment and there is no placebo group. The study does not involve any medications. Participants must not have certain medical conditions, electronic or metal implants in or near the head, untreated sleep apnea, or active serious psychiatric disorders. Participants who are pregnant or breastfeeding cannot take part.

Study Overview

• Status: Not yet recruiting
• Conditions: Insomnia; Sleep Disturbance; Chronic Insomnia; Chronic Insomnia Disorder
• Intervention / Treatment: Device: TMS

Detailed Description

BACKGROUND AND RATIONALE

Chronic insomnia disorder affects approximately 10-12% of adults worldwide and is associated with increased risk of psychiatric disorders, cardiovascular disease, and reduced quality of life. While cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment, access remains limited. Pharmacological options carry concerns regarding long-term efficacy, dependency, and adverse effects.

The hyperarousal model of insomnia suggests that excessive activation of arousal systems contributes to the disorder. The left dorsolateral prefrontal cortex (DLPFC) has been identified as a critical node in insomnia pathophysiology, with altered functional connectivity patterns correlating with poor sleep quality and changes in sleep architecture, including increased beta/gamma activity and reduced slow-wave sleep. These findings support the rationale for targeted neuromodulation of this brain region.

Low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the DLPFC has demonstrated improvements in both subjective sleep quality and objective sleep parameters, with reported response rates of approximately 55% and remission rates of approximately 68%. Protocols using 3-4 sessions per week have shown sustained benefits at 6-12 month follow-up. However, most prior studies have relied primarily on subjective outcome measures with limited polysomnographic or EEG-based sleep data, and optimal stimulation parameters and age-related differences in treatment response remain poorly characterized.

STUDY PROCEDURES

Screening Phase (Day -25 to Day -1):

Screening is conducted in two parts. Part 1 (Day -25 to Day -15) includes a general health assessment, medical history review, vital signs, and subjective sleep evaluation using the Consensus Sleep Diary - Morning Administration (CSD-M) collected over a minimum of 7 consecutive days and the Insomnia Severity Index (ISI). Subjects taking hypnotic medications at the time of consent must complete a minimum 5-day washout before CSD-M and ISI administration. CSD-M data from Part 1 are also used to determine each participant's median habitual bedtime for standardizing subsequent at-home sleep monitoring.

Part 2 (Day -14 to approximately Day -5) includes objective sleep assessment using the Somfit™ home EEG device over 2 consecutive nights. The first night's recording is used to screen for periodic limb movements/restless legs syndrome, sleep-disordered breathing, and parasomnias. Both nights' recordings are used to confirm objective insomnia criteria. Two training sessions for the cognitive test battery and body sway assessments are also completed during Part 2 to reduce learning effects.

For subjects aged 65 years and older, a Mini-Mental State Examination (score ≥25 required) is administered during screening to ensure capacity for safe participation. Motor threshold determination is also performed during screening to calibrate stimulation intensity; the motor threshold is defined as the minimum stimulus intensity required to induce visible contraction of the right thumb.

Open-Label Treatment Phase (Day 1 to approximately Day 14):

The night before the first treatment session, participants complete an at-home Somfit™ sleep recording to establish baseline objective sleep data. On Day 1, pre-treatment assessments are completed, including vital signs, CSD-M, ISI, Pittsburgh Sleep Quality Index (PSQI), Clinical Global Impression - Severity (CGI-S), Patient Global Impression - Severity (PGI-S), and Perceived Stress Scale (PSS).

Treatment consists of 6 rTMS sessions administered 3 times per week over 2 weeks using the EXOMIND™ device (BTL-699-2). Each session delivers 6,300 pulses at alternating frequencies of 12, 15, and 18 Hz, with a total session duration of 24 minutes and 30 seconds. The stimulation target is the left DLPFC, localized using the standard 5.5-cm anterior method. All sessions are conducted at the research site with medical staff present. Blood pressure and heart rate are recorded at the beginning and end of each session, and adverse events are monitored using a standardized checklist derived from existing TMS safety literature.

On the day of the 6th (final) treatment session, post-treatment assessments are completed, including vital signs, CSD-M, PSQI, ISI, CGI-S, CGI - Improvement (CGI-I), PGI-S, PGI - Improvement (PGI-I), and PSS.

Follow-Up Phase:

Participants return for follow-up visits at 1 month and 3 months after the last treatment session. Safety assessments and outcome measures are repeated at each visit. If a participant withdraws prematurely, end-of-study assessments are performed as soon as possible.

OBJECTIVE SLEEP MONITORING

Objective sleep architecture is assessed using the Somfit™ home EEG monitoring device at screening (2 nights), baseline (1 night before Day 1), and at post-treatment and follow-up time points. Parameters recorded include sleep onset latency (SOL), wake after sleep onset (WASO), total sleep time (TST), sleep efficiency (SE), Stage N3 duration, and slow-wave activity (SWA).

AGE GROUP COMPARISON

The study enrolls both adult (18-64 years) and elderly (65-85 years) participants, with approximately equal proportions targeted in each group (neither group exceeding approximately 60% of total enrollment). This design allows exploratory comparison of treatment response across age groups, addressing a gap in the existing literature regarding age-related differences in rTMS efficacy for insomnia.

STATISTICAL APPROACH

Descriptive statistics will summarize demographic and baseline characteristics. The primary analysis will use repeated measures ANOVA to assess changes in outcome scores across four time points (baseline, post-intervention, 1-month follow-up, and 3-month follow-up). Paired t-tests will evaluate within-subject changes in secondary measures between baseline and each post-treatment time point. A p-value of less than 0.05 will be considered statistically significant.

• Study Type: Interventional
• Enrollment (Estimated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Joy Shihui Meng, MD; Phone Number: 4156662536; Email: office@sf-neurology.com
• Study Contact Backup: Name: Junyi Sun, MD, PhD; Phone Number: 4156662536; Email: office@sf-neurology.com

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94110
      • San Francisco Neurology and Sleep Center
      • Contact: Junyi Sun, MD, PhD; Phone Number: 4156662536; Email: office@sf-neurology.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subject must be 18 to 85 years of age, inclusive, on the day of signing informed consent.
• Subject must meet DSM-5 criteria for insomnia disorder：

A predominant complaint of dissatisfaction with sleep quantity or quality, associated with one (or more) of the following symptoms:

Difficulty initiating sleep Difficulty maintaining sleep, characterized by frequent awakenings or problems returning to sleep after awakenings Early-morning awakening with inability to return to sleep. The sleep disturbance causes clinically significant distress or impairment in social, occupational, educational, academic, behavioral, or other important areas of functioning.

The sleep difficulty occurs at least 3 nights per week. The sleep difficulty is present for at least 3 months. The sleep difficulty occurs despite adequate opportunity for sleep. The insomnia is not better explained by and does not occur exclusively during the course of another sleep-wake disorder (eg, narcolepsy, a breathing-related sleep disorder, a circadian rhythm sleep-wake disorder, a parasomnia).

The insomnia is not attributable to the physiological effects of a substance (eg, a drug of abuse, a medication).

Coexisting mental disorders and medical conditions do not adequately explain the predominant complaint of insomnia.

• Subject must have an ISI total score ≥15 at screening.
• Subject must have an sSOL ≥45 minutes and an sWASO ≥60 minutes on at least 3 nights over any 7-day period during Part 1 of screening, using the CSD-M, prior to screening Somfit™ sleep test assessments.
• Subject must demonstrate a 2-night mean SOL of ≥25 minutes (with neither night <20 minutes), a 2-night mean WASO ≥30 minutes, and a 2-night mean TST ≤6.5 hours, with neither night >7 hours.
• Subject must be otherwise healthy or present with stable, well-controlled, chronic conditions on the basis of physical examination, medical history, vital signs, 12-lead ECG (if necessary), and clinical laboratory tests (if necessary) performed at screening. If there are abnormalities, they must be consistent with the underlying illness in the study population. If the results of the clinical laboratory tests are outside the normal reference ranges, the subject may be included only if the investigator and the sponsor's Safety Physician judge the abnormality or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initiated by the investigator.
• Body mass index between 18 and 35 kg/m2 inclusive (body mass index = weight/height^2).
• For subjects ≥65 years of age, a Mini-Mental State Examination score of ≥25 to rule out cognitive impairment in the interest of subject safety.
• Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the right thumb.
• Subjects willing and able to abstain from partaking in any treatments other than the study procedure for the improvement in sleep quality and reduction of stress, including non-invasive brain stimulation treatments other than the study procedure during study participation.
• Subjects willing and able to maintain their regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation.
• Willingness to comply with study instructions and to return to the clinic for the required visits.
• Women of child-bearing potential are required to use birth control measures during the whole duration of the study.
• If applicable, subjects will be maintained on pre-study prescribed medications at a stable therapeutic dosage for at least 2 months prior to study entry.
• Subject is not using any sleeping medication or is using over-the-counter pills (except Valerian and St. John's Wort) no more than 4 times a week.
• Subject must usually spend between 6 and 9 hours in bed during the night and go to bed between 8 PM and 1 AM and typically get out of bed between 5 AM and 9 AM.
• Subject must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
• Subjects must sign a separate ICF if he or she agrees to provide an optional DNA sample for research (where local regulations permit). Refusal to give consent for the optional DNA research samples does not exclude a subject from participation in the study.

Exclusion Criteria:

• Has history of or current clinically significant and/or unstable liver (moderate or severe hepatic impairment [Child-Pugh Score ≥7]) or renal insufficiency (severe renal impairment [estimated creatinine clearance below 30 mL/min]; serum creatinine >2 mg/dL); significant and/or unstable cardiac, vascular, pulmonary (eg, acute or severe respiratory failure), gastrointestinal, endocrine, neurologic (eg, myasthenia gravis, narcolepsy), hematologic, rheumatologic, immunologic, or metabolic disturbances. Organic brain disease, epilepsy, dementia, narcolepsy, narrow angle glaucoma and known or suspected mental retardation are exclusionary. Any clinically relevant medical condition that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study (eg, medically frail subject with history of hospitalization due to fractures) or could potentially alter the absorption, metabolism, or excretion of the study drug is exclusionary.

Note: Subjects with chronic but stable, well-controlled conditions may be allowed in the study upon agreement with the investigator and the sponsor's Safety Physician.

• Has uncontrolled hypertension (supine systolic blood pressure >150 mm Hg in adult subjects or >160 mm Hg in elderly subjects or supine diastolic blood pressure >90 mm Hg, despite diet, exercise, or a stable dose of allowed antihypertensive therapy) at screening or Day 1. (A subject with hypertension may be included if the subject's hypertension has been controlled for at least 3 months prior to screening, and the dosage of any antihypertensive medication has been stable for the past 3 months).
• Has clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening. Subjects with non-insulin dependent diabetes mellitus who are adequately controlled (hemoglobin A1c [HbA1c] ≤8%) may be eligible to participate if otherwise medically healthy. It is expected that laboratory values will generally be within the normal range, though minor deviations, which are not considered to be of clinical significance to both the investigator and the sponsor's Safety Physician, are acceptable.
• Has clinically significant ECG abnormalities at screening or Day 1 prior to treatment defined as:

T interval corrected according to Fridericia's formula: ≥450 msec (males);

≥470 msec (females). Evidence of 2nd and 3rd degree atrioventricular block, or 1st degree atrioventricular block with PR interval >210 msec, left bundle branch block.

Features of new ischemia. Other clinically important arrhythmia. Note: Subjects with right bundle branch block may be allowed provided confirmation that right bundle branch block is not associated with underlying cardiac/lung diseases.

• Electronic implants in or near the head - rTMS devices are contraindicated for use in patients who have active or inactive implants in or near the head including device leads, deep brain stimulators, cochlear implants, ocular implants, and vagus nerve stimulators, implanted devices such as cardiac pacemakers, defibrillators, and neurostimulators.
• Metallic, ferromagnetic or other magnetic-sensitive implants/objects in or near the head - rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head (with some exceptions in the mouth - see Operator's Manual) or within 12 in (30 cm) of the therapy coil. (Examples include implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry, hair barrettes and tattoos with metallic ink), drug pumps (within 12 in (30 cm) of the therapy coil) application in the heart area.
• Has significant hypersomnia not related to night time insomnia (based on clinical judgment of the investigator).
• Moderate-to-severe obstructive sleep apnea (AHI ≥15 events/hour) that is untreated or inadequately controlled (residual AHI ≥5 events/hour on CPAP therapy).
• Regularly naps more than 3 times per week.
• Has a current diagnosis or recent history of psychotic disorder, MDD, bipolar disorder, or posttraumatic stress disorder, or other psychiatric condition that, in the investigator's opinion, would interfere with the subject's ability to participate in the trial.
• Has a current or recent history of serious suicidal ideation within the past 6 months, or a history of suicidal behavior within the past year. Subjects with a prior suicide attempt of any sort, or prior serious suicidal ideation/plan within the past 6 months, should be carefully screened for current suicidal ideation and only subjects with non-serious items may be included at the discretion of the investigator.
• Has insomnia related to RLS (defined as PLM-arousal index of ≥10 PLM-related electroencephalograph (EEG) arousals per hour of sleep for adult subjects or >15 for elderly subjects), sleep breathing disorder (defined as an apnea-hypopnea index ≥10 cumulative apneas and hypopneas per hour of EEG sleep for adult subjects or >15 for elderly subjects), or parasomnias. These disorders will be ruled out by the first PSG recording during Part 2 of screening.
• Is a shift worker or has a significantly shifted diurnal activity pattern.
• Has experienced transmeridian travel across 2 or more time zones within the 2 weeks prior to screening, or plans to travel across 2 or more time zones during study participation.
• Has a known malignancy or history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, that in the opinion of the investigator, with the concurrence with the sponsor's Safety Physician, is considered cured with minimal risk of recurrence).
• Has a history of substance or alcohol use disorder of moderate to severe severity according to DSM-5 criteria within 6 months before screening or positive test result(s) for alcohol or drugs of abuse (including barbiturates, opiates [including methadone], cocaine, cannabinoids, methamphetamines, amphetamines, 3,4-Methylenedioxymethamphetamine, and BZD) at screening or at baseline.
• Smokes >10 cigarettes per day and/or has quit smoking within 1 month prior to screening.
• Consumes >500 mg of caffeine per day in any form (tea/coffee/cocoa/cola/energy drinks) averagely. Refer to caffeineinformer.com/the-caffeine-database for average caffeine content of various beverages.
• Had clinically significant acute illness within 7 days prior to study rTMS treatment.
• Is under ongoing psychological treatments focused on insomnia (eg, Cognitive Behavior Therapy), initiated within 2 months prior to Day 1. A subject who has been receiving ongoing psychological treatment for a period of greater than 2 months is eligible, if the investigator deems the psychological treatment to be of stable duration and frequency. The subject's psychological treatment should be maintained during participation in the study.
• Has donated 1 or more units (approximately 450 mL) of blood or acute loss of an equivalent amount of blood within 60 days prior to study.
• Is pregnant or breastfeeding while enrolled in this study or within 1 month after the last session of study rTMS treatment.
• Has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 3 months before the planned first dose of study drug or is currently enrolled in an investigational study.
• Has psychologic and/or emotional problems, which would render the informed consent invalid, or limit the ability of the subject to comply with the study requirements, or is a vulnerable subject due to involuntary detention (such as for legal reasons).
• Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.
• Has had major surgery, (eg, requiring general anesthesia) within 2 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study. Note: Subjects with planned surgical procedures to be conducted under local anesthesia may participate.
• Is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: rTMS Treatment; Participants receive 6 sessions of repetitive transcranial magnetic stimulation (rTMS) using the EXOMIND™ device (BTL-699-2), administered 3 times per week over 2 weeks. Each session delivers 6,300 magnetic pulses at alternating frequencies of 12, 15, and 18 Hz to the left dorsolateral prefrontal cortex (DLPFC), localized using the standard 5.5-cm anterior method. Total session duration is 24 minutes and 30 seconds. Stimulation intensity is calibrated to each participant's individual motor threshold, defined as the minimum stimulus required to produce visible contraction of the right thumb. All sessions are conducted on-site at the research center with medical staff present. Blood pressure and heart rate are monitored before and after each session.

Device: TMS; The EXOMIND™ (BTL-699-2) is a repetitive transcranial magnetic stimulation (rTMS) device that delivers targeted electromagnetic pulses to cortical brain regions. In this study, stimulation is applied to the left dorsolateral prefrontal cortex (DLPFC), a region implicated in executive function, working memory, and attention. The DLPFC target is localized using the standard 5-cm rule, measured anterior to the motor cortex hot spot. Each treatment session uses a multi-frequency protocol alternating between 12, 15, and 18 Hz stimulation frequencies, delivering a total of 6,300 pulses over 24 minutes and 30 seconds. Stimulation intensity is calibrated to each participant's resting motor threshold, defined as the minimum stimulus intensity required to produce a visible contraction of the right abductor pollicis brevis muscle. Six sessions are administered twice weekly over approximately 3 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Insomnia Severity Index (ISI) Total Score at 1-Month Follow-Up	The Insomnia Severity Index (ISI) is a 7-item self-report questionnaire that assesses the nature, severity, and impact of insomnia. Each item is rated on a 0-4 Likert scale, yielding a total score ranging from 0 to 28. Higher scores indicate greater insomnia severity. Clinical severity categories are: 0-7 (no clinically significant insomnia), 8-14 (subthreshold insomnia), 15-21 (moderate clinical insomnia), and 22-28 (severe clinical insomnia). The primary outcome is the change in ISI total score from baseline (Day 1, pre-treatment) to the 1-month follow-up visit. A negative change indicates improvement.	From baseline to the 1-month follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Sleep Onset Latency (SOL)	Sleep onset latency (SOL) is defined as the time in minutes from lights off to the first epoch of any sleep stage, as measured by the Somfit™ home EEG recording device. A negative change from baseline indicates faster sleep onset and improvement.	Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Stage N3 Duration	Stage N3 duration is defined as the total time in minutes spent in N3 (deep/slow-wave) sleep during the recording period, as measured by the Somfit™ home EEG recording device. N3 sleep is the deepest stage of non-REM sleep and is associated with restorative functions. A positive change from baseline indicates an increase in deep sleep and improvement.	Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Wake After Sleep Onset (WASO)	Wake after sleep onset (WASO) is defined as the total time in minutes spent awake after initial sleep onset until the final awakening, as measured by the Somfit™ home EEG recording device. A negative change from baseline indicates less nighttime wakefulness and improvement.	Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Total Sleep Time (TST)	Total sleep time (TST) is defined as the total time in minutes spent in any sleep stage (N1, N2, N3, and REM) during the recording period, as measured by the Somfit™ home EEG recording device. A positive change from baseline indicates more sleep and improvement.	Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Sleep Efficiency (SE)	Sleep efficiency (SE) is defined as the percentage of total time in bed spent asleep, calculated as (total sleep time / total time in bed) × 100, as measured by the Somfit™ home EEG recording device. A positive change from baseline indicates improved sleep efficiency.	Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Slow-Wave Activity (SWA)	Slow-wave activity (SWA) is defined as the EEG spectral power in the low-frequency range (typically 0.5-4.0 Hz) during non-REM sleep, as measured by the Somfit™ home EEG recording device. SWA is a quantitative marker of sleep depth and homeostatic sleep pressure. A positive change from baseline indicates enhanced deep sleep intensity and improvement.	Baseline (night before Day 1), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Insomnia Severity Index (ISI) Total Score at Day 21 and 3-Month Follow-Up	The Insomnia Severity Index (ISI) is a 7-item self-report questionnaire that assesses the nature, severity, and impact of insomnia. Each item is rated on a 0-4 Likert scale, yielding a total score ranging from 0 to 28. Higher scores indicate greater insomnia severity. Clinical severity categories are: 0-7 (no clinically significant insomnia), 8-14 (subthreshold insomnia), 15-21 (moderate clinical insomnia), and 22-28 (severe clinical insomnia). This secondary outcome captures the change in ISI total score from baseline to the day of the last rTMS session and to the 3-month follow-up visit. A negative change indicates improvement. The 1-month follow-up ISI assessment is captured separately as the primary outcome measure.	Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), and 3-month follow-up (approximately Day 111)
Change From Baseline in Subjective Sleep Parameters as Measured by the Consensus Sleep Diary - Morning Administration (CSD-M)	The Consensus Sleep Diary - Morning Administration (CSD-M) is a standardized self-report instrument completed each morning to capture subjective sleep parameters from the prior night. Key parameters include subjective sleep onset latency (sSOL), subjective wake after sleep onset (sWASO), subjective total sleep time (sTST), time in bed, subjective sleep efficiency, number of awakenings, and subjective sleep quality rating. Changes from baseline in these diary-derived parameters will be assessed. Improvements are indicated by decreased sSOL and sWASO, increased sTST and sleep efficiency, and higher sleep quality ratings.	Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)	The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire that assesses sleep quality and disturbances over the preceding one-month period. It yields seven component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction), each scored from 0 to 3. The seven component scores are summed to produce a global PSQI score ranging from 0 to 21. A global score greater than 5 indicates poor sleep quality. A negative change from baseline indicates improvement in sleep quality.	Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Patient Global Impression - Improvement (PGI-I)	The Patient Global Impression - Improvement (PGI-I) is a single-item self-report measure in which the subject rates the overall change in their insomnia since the start of the study on a 7-point Likert scale ranging from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. Lower scores indicate greater perceived improvement. As this is a post-baseline measure of change, there is no baseline value; scores are assessed at each post-treatment time point.	Day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Patient Global Impression - Severity (PGI-S)	The Patient Global Impression - Severity (PGI-S) is a single-item self-report measure in which the subject rates the current severity of their insomnia on a 7-point Likert scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). A negative change from baseline indicates the subject perceives a reduction in insomnia severity and improvement.	Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Clinical Global Impression - Severity (CGI-S)	The Clinical Global Impression - Severity (CGI-S) is a single-item clinician-rated measure in which the investigator rates the current severity of the subject's insomnia on a 7-point Likert scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill). The rating is based on the clinician's total clinical experience with the insomnia population. A negative change from baseline indicates the clinician perceives a reduction in insomnia severity and improvement.	Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Clinical Global Impression - Improvement (CGI-I)	The Clinical Global Impression - Improvement (CGI-I) is a single-item clinician-rated measure in which the investigator rates the overall change in the subject's insomnia since the start of the study on a 7-point Likert scale ranging from 1 (very much improved) to 7 (very much worse), with 4 indicating no change. Lower scores indicate greater clinician-assessed improvement. As this is a post-baseline measure of change, there is no baseline value; scores are assessed at each post-treatment time point.	Day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)
Change From Baseline in Perceived Stress Level as Measured by the Perceived Stress Scale (PSS)	The Perceived Stress Scale (PSS) is a 10-item self-report questionnaire that measures the degree to which situations in a respondent's life are appraised as stressful over the preceding one-month period. Each item is rated on a 5-point Likert scale ranging from 0 (never) to 4 (very often). Total scores range from 0 to 40, with higher scores indicating greater perceived stress. Score categories are: 0-13 (low stress), 14-26 (moderate stress), and 27-40 (high perceived stress). Elevated perceived stress has been associated with insomnia severity and may serve as a mediator of treatment response. A negative change from baseline indicates a reduction in perceived stress and improvement.	Baseline (Day 1, pre-treatment), day of last rTMS session (approximately Day 21), 1-month follow-up (approximately Day 51), and 3-month follow-up (approximately Day 111)

Collaborators and Investigators

• Sponsor: San Francisco Neurology and Sleep Center

Publications and helpful links

General Publications

• Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016 Jul 19;165(2):125-33. doi: 10.7326/M15-2175. Epub 2016 May 3.
• Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Feb 15;13(2):307-349. doi: 10.5664/jcsm.6470.
• Riemann D, Nissen C, Palagini L, Otte A, Perlis ML, Spiegelhalder K. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2015 May;14(5):547-58. doi: 10.1016/S1474-4422(15)00021-6. Epub 2015 Apr 12.
• Lu Q, Gu H, Jiang Z, Yang Q, Hu W, He C. Reduced coupling between global brain activity and cerebrospinal fluid flow in middle-aged and older adults with chronic insomnia: enhancement by low-frequency rTMS. Sleep. 2026 Feb 4:zsag016. doi: 10.1093/sleep/zsag016. Online ahead of print.
• Sun J, Li P, Yi Y, Xu W, Zhang G, Zhang B, Ding K, Luo S, Zhou J. Effects of mPFC-rTMS in chronic Insomnia: A randomized, double-blind, placebo-controlled study. Sleep Med. 2025 Oct;134:106704. doi: 10.1016/j.sleep.2025.106704. Epub 2025 Jul 29.
• Gong L, Yang X, He Y, Li H, Zhou W, Liu D, Zhang B, Xi C. Precision targeting of right dorsolateral prefrontal cortex with neuronavigated rTMS alleviates chronic insomnia via functional connectivity reorganization: a randomized neuroimaging trial. Neuroimage Clin. 2025;47:103815. doi: 10.1016/j.nicl.2025.103815. Epub 2025 Jun 4.
• Van Someren EJW. Brain mechanisms of insomnia: new perspectives on causes and consequences. Physiol Rev. 2021 Jul 1;101(3):995-1046. doi: 10.1152/physrev.00046.2019. Epub 2020 Aug 13.
• Morin CM, Buysse DJ. Management of Insomnia. N Engl J Med. 2024 Jul 18;391(3):247-258. doi: 10.1056/NEJMcp2305655. No abstract available.
• van Straten A, Weinreich KJ, Fabian B, Reesen J, Grigori S, Luik AI, Harrer M, Lancee J. The Prevalence of Insomnia Disorder in the General Population: A Meta-Analysis. J Sleep Res. 2025 Oct;34(5):e70089. doi: 10.1111/jsr.70089. Epub 2025 May 14.

Study record dates

Study Major Dates

• Study Start (Estimated): May 20, 2026
• Primary Completion (Estimated): May 19, 2028
• Study Completion (Estimated): June 30, 2028

Study Registration Dates

• First Submitted: May 12, 2026
• First Submitted That Met QC Criteria: May 12, 2026
• First Posted (Actual): May 19, 2026

Study Record Updates

• Last Update Posted (Actual): May 19, 2026
• Last Update Submitted That Met QC Criteria: May 12, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Insomnia; Sleep Efficiency; Chronic Insomnia Disorder
• Additional Relevant MeSH Terms: Nervous System Diseases; Mental Disorders; Sleep Wake Disorders; Sleep Disorders, Intrinsic; Dyssomnias; Parasomnias; Sleep Initiation and Maintenance Disorders
• Other Study ID Numbers: SFNSC-2026-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes